

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Shanghai Henlius Biotech, Inc.

上海復宏漢霖生物技術股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 2696)

**RESIGNATION OF CHIEF FINANCIAL OFFICER
AND
APPOINTMENT OF CHIEF FINANCIAL OFFICER**

RESIGNATION OF CHIEF FINANCIAL OFFICER

The board of directors (the “**Board**”) of Shanghai Henlius Biotech, Inc. (the “**Company**”) announces that Mr. Xinlei Li (“**Mr. Li**”) has tendered his resignation as the vice president and the Chief Financial Officer of the Company with effect from 30 April 2023, due to personal development reason.

Mr. Li has confirmed that he has no disagreement with the Board and there is no matter in relation to his resignation which needs to be brought to the attention of the shareholders of the Company and The Stock Exchange of Hong Kong Limited. The Board would like to express its gratitude to Mr. Li for his efforts during his tenure of office as vice president and the Chief Financial Officer of the Company.

APPOINTMENT OF CHIEF FINANCIAL OFFICER

The Board is pleased to announce that Mr. Jun Zhu (“**Mr. Zhu**”) has been appointed as the Chief Financial Officer of the Company with effect from 1 May 2023.

Mr. Jun Zhu, aged 45, has joined the Group since December 2020, and currently serves as the president and Chief Financial Officer of the Company and holds directorship and other positions in certain subsidiaries of the Company. Before joining the Group, Mr. Zhu served as the internal medicine physician in Huashan Hospital affiliated to Fudan University in Shanghai, the project manager and global vice-president of IQVIA Holdings Inc., the general manager of Omnicare Clinical Research Inc. in Greater China, the founder and chief executive officer of Shanghai PPC Biopharmaceutical Technology Co., Ltd.* (上海百利佳生醫藥科技有限公司). Mr. Zhu obtained a bachelor's degree in clinical medicine from Fudan University (復旦大學) in China in July 2001 and an EMBA degree from Cheung Kong Graduate School of Business (長江商學院) in China in September 2018.

The Board would like to take this opportunity to welcome Mr. Zhu for his new position within the Group.

On behalf of the Board
Shanghai Henlius Biotech, Inc.
Wenjie ZHANG
Chairman

Hong Kong, 1 May 2023

As at the date of this announcement, the Board of Directors of the Company comprises Mr. Wenjie Zhang as the chairman and executive director, Mr. Qiyu Chen, Mr. Yifang Wu, Ms. Xiaohui Guan, Mr. Deyong Wen and Mr. Zihou Yan as the non-executive directors, and Mr. Tak Young So, Dr. Lik Yuen Chan, Dr. Guoping Zhao and Dr. Ruilin Song as the independent non-executive Directors.

* *For identification purpose only*